Yes, as I said, Joe had his reasons for the 400MM shares. However, he made that decision without a current professional valuation for NGIO, only with comps.
My point is that, at $4/sh (which is what I believe we need without significant revs, etc, Hy), we are not necessarily dead in the water if the valuation is under $1.6B.
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links